Table 3.
Potencies of nutlin-3a and navtemadlin measured under normoxic and hypoxic conditions in cancer cell lines expressing wild-type p53.
| Cell line | nutlin-3a | navtemadlin | ||||
|---|---|---|---|---|---|---|
| Normoxia IC50 (95% CI) | Hypoxia IC50 (95% CI) | Padj | Normoxia IC50 (95% CI) | Hypoxia IC50 (95% CI) | Padj | |
| HCT116 p53+/+ | 1.6 (1.3–1.9) | 1.4 (1.1–1.6) | 0.99 | 0.3 (0.3–0.4) | 0.3 (0.2–0.4) | 0.99 |
| MCF7 | 1.8 (0.9–2.8) | 2.7 (0–8.8) | 0.96 | 0.2 (0.2–0.3) | 0.3 (0.1–0.4) | 0.95 |
| B16-F10 p53+/+ | 8.6 (6.9–10.3) | 6.9 (3.2–10.2) | 0.74 | 1.4 (1.2–1.5) | 1.3 (1.0–1.7) | 0.96 |
Potency was calculated as the concentration of drug that reduced cell growth by 50% of the untreated control (IC50), as measured by a cellular viability assay. Cellular confluence was measured after 72 h of exposure to 10 drug concentrations.
CI confidence interval.